GPAT vs GPATW: Equity Shares and Warrants of GP-Act III Acquisition Corp.
Key Takeaways
- Same issuer, different instruments: GPAT and GPATW are two classes of securities issued by the same company, GP-Act III Acquisition Corp., a special purpose acquisition company (SPAC) — a blank-check vehicle formed to merge with a private business.
- GPAT is the equity: Class A ordinary shares trade close to the cash value held in the company's trust account, giving them a relatively stable, downside-protected profile.
- GPATW is a leveraged derivative: The redeemable warrants are long-dated options with an $11.50 exercise price, making them far more volatile and sensitive to deal progress than the shares.
- Divergent risk-reward: The shares offer capital preservation with modest upside, while the warrants offer high potential returns but carry a materially higher risk of losing their value.
- Catalyst-driven: Both securities are heavily influenced by the company's ability to complete a business combination before its extended deadline.
Setting the Stage
When investors compare GPAT and GPATW, they are really looking at two distinct ways to gain exposure to the same underlying SPAC. GP-Act III Acquisition Corp. is a blank-check company that raised funds through an IPO with the goal of merging with a private business. This distinction matters for event-driven traders who track SPAC timelines and announcements, as well as for those deciding between a more conservative equity holding and a higher-risk warrant position. I find it useful to examine how these instruments move and why their behaviors diverge so noticeably.
GPAT Shares in Focus
GPAT represents the Class A ordinary shares of GP-Act III Acquisition Corp., a Cayman Islands company sponsored by an affiliate of GP Investments. The SPAC completed its IPO in May 2024, raising about $287.5 million, most of which sits in a trust account invested in permitted securities. Recently the shares have stayed in a tight range near the estimated trust redemption value, a common pattern for SPACs without a definitive merger target yet. The company continues to seek extensions for its business combination deadline and has used non-redemption agreements to help protect the trust. This stability points to a capital-preservation focus rather than aggressive upside.
GPATW Warrants in Focus
GPATW covers the redeemable warrants of the same SPAC. Each whole warrant allows the holder to buy one Class A share at an $11.50 exercise price. These warrants have recently traded at low prices amid uncertainty over whether and when a qualifying merger will occur. Because they function like long-dated options, their value reacts strongly to time remaining, deal progress, and the chance that shares eventually exceed the strike. With shares near trust value and the exercise price above current levels, the warrants carry notable time decay and execution risk, which explains their higher volatility compared with the equity.
Direct Comparison
The core difference lies in the instruments themselves. GPAT shares carry partial backing from the trust cash, creating a floor that limits downside in a liquidation. GPATW warrants lack this protection and depend entirely on shares surpassing $11.50 before expiration or redemption. Both share the same primary catalyst—the completion and quality of a business combination—but the payoff profiles differ sharply. Shares deliver steadier, trust-linked exposure with limited appreciation until a deal emerges, while warrants provide leveraged upside to positive news. On risk, warrants face greater time decay, redemption pressure, and the chance of expiring worthless; shares mainly contend with opportunity cost and a narrow spread to trust value. Neither has operating-sector exposure yet, and market sentiment for the shares stays tied to the trust while warrant pricing reflects speculation on deal timing. I also checked this using Tickeron’s AI Screener to see how the pair compares within the broader SPAC space.
AI Assessment
Considering factors such as trend consistency, stability, catalysts, and positioning, the AI evaluation tends to favor GPAT over GPATW right now. The shares show a more consistent, lower-volatility pattern anchored by trust value, which generally scores better on stability measures. The warrants, despite greater upside potential, reflect weaker trend consistency and higher uncertainty around merger timing. This view emphasizes relative strength in downside protection rather than a firm forecast, and it could change with clearer deal details.
Exploring Automated Strategies
In my own analysis of SPAC names, I often review Tickeron’s Trending AI Robots to see which automated strategies align with current conditions. The section features bots that have performed well across different market regimes, offering a practical way to evaluate data-driven approaches without building everything from scratch. This has helped me cross-check ideas on instruments like these before making allocation decisions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
GPAT in upward trend: 10-day moving average moved above 50-day moving average on October 01, 2026
The 10-day moving average for GPAT crossed bullishly above the 50-day moving average on October 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 25%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 2 of 22 cases where GPAT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 9%.
The Momentum Indicator moved above the 0 level on October 01, 2026. You may want to consider a long position or call options on GPAT as a result. In 4 of 45 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 9%.
The Moving Average Convergence Divergence (MACD) for GPAT just turned positive on October 05, 2026. Looking at past instances where GPAT's MACD turned positive, the stock continued to rise in 2 of 36 cases over the following month. The odds of a continued upward trend are 6%.
GPAT moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Bearish Trend Analysis
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. GPAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.173) is normal, around the industry mean (132.155). P/E Ratio (44.000) is within average values for comparable stocks, (171.505). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (15.932). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. GPAT's P/S Ratio (0.000) is very low in comparison to the industry average of (3.158).
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GPAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry FinancialConglomerates
Advertisement